Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

33c461dc2ef4b41f552.MhqisgDgJJIUvtK4gN2olfSM4GPUDQOgra4Ke_uemnI.YXWa-jOlHNFe8LPP6becxa3oglunPkST3ZxAP4L97RlXcez0YtkQ-lbM5g~08c9243633df637b16bf82e1fcd68547
06-08 Gilead Sciences Faces Potential Threat From In Vivo CAR-T, RBC Says MT
05-20 Maxim Upgrades Gilead Sciences to Buy From Hold, Price Target is $165 MT
05-19 Daiwa Securities Adjusts PT on Gilead Sciences to $150 From $161, Maintains Outperform Rating MT
05-11 Gilead's Emvistegrast Readout Unlikely to Move Stock, RBC Says MT
05-11 Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 From $170 MT
05-08 Leerink Partners Adjusts Price Target on Gilead Sciences to $146 From $148 MT
05-08 Gilead Sciences' Increased Yeztugo Guidance is 'Good Enough' for the Stock, Morgan Stanley Says MT
05-08 Morgan Stanley Adjusts Price Target on Gilead Sciences to $168 From $175 MT
04-28 Morgan Stanley Adjusts Gilead Sciences Price Target to $175 From $171, Maintains Overweight Rating MT
04-17 Goldman Sachs Adjusts Gilead Sciences Price Target to $130 From $125, Maintains Neutral Rating MT
04-17 Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $155 From $115, Maintains Overweight Rating MT
04-13 Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating MT
04-10 Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $115 From $155, Maintains Overweight Rating MT
04-08 Gilead Sciences' Tubulis Buy Underscores Shift Beyond HIV, Oppenheimer Says MT
04-07 RBC Adjusts Price Target on Gilead Sciences to $123 From $118, Maintains Sector Perform Rating MT
03-31 Gilead Sciences Shows Solid Early Yeztugo Persistence but Limited Market Expansion, RBC Says MT
02-25 Daiwa Securities Adjusts Price Target on Gilead Sciences to $161 From $129, Maintains Outperform Rating MT
02-25 Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead… Zonebourse
02-24 Gilead Sciences Acquiring Arcellx to Consolidate Anito-Cel Ownership, UBS Securities Says MT
02-20 Barclays Initiates Coverage on Gilead Sciences With Equal Weight Rating MT
02-19 Argus Adjusts Price Target on Gilead Sciences to $165 From $135, Maintains Buy Rating MT
02-18 Mizuho Securities Lifts Gilead Sciences Price Target to $170 From $140, Maintains Outperform Rating MT
02-17 Rothschild & Co Redburn Adjusts Gilead Sciences PT to $170 From $159, Maintains Buy Rating MT
02-16 Analyst recommendations: Eagle Materials, Coinbase Global, Gilead Sciences, Royal Gold… Zonebourse
02-12 Wolfe Adjusts Price Target on Gilead Sciences to $170 From $155, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+25.39%
+4.72%
+6.1%
+12.8%
+10.9%
+7.44%
+21.97%
+1.93%
+10.34%
-0.44%
Average +10.12%
Weighted average by Cap. +8.53%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
125.59USD
Average target price
157.83USD
Spread / Average Target
+25.67%
High Price Target
180.00USD
Spread / Highest target
+43.32%
Low Price Target
122.00USD
Spread / Lowest Target
-2.86%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Maxim
Daiwa Securities
Rothschild & Co Redburn
Leerink Partners
Morgan Stanley
Goldman Sachs
Cantor Fitzgerald
Citigroup
RBC Capital Markets
Barclays
Argus
Mizuho Securities
Wolfe Research
TD Cowen
Deutsche Bank Securities
Needham & Co.
Oppenheimer
BMO Capital
Bernstein
Scotiabank
Baird
Wells Fargo Securities
JPMorgan Chase
UBS
HSBC
Truist Securities
DBS Bank
BofA Securities
Jefferies & Co.
Redburn Atlantic
Piper Sandler
Raymond James
SVB Securities LLC
Cowen
SVB Leerink
Credit Suisse
Redburn
DZ BANK Elmar Kraus
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
125.59USD
Average target price
157.83USD
Spread / Average Target
+25.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock
  4. Consensus Gilead Sciences, Inc.
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!